


**Product Name** : Ulixertinib hydrochloride  
**Cat. No.** : PC-20223  
**CAS No.** : 1956366-10-1  
**Molecular Formula** : C<sub>21</sub>H<sub>23</sub>Cl<sub>3</sub>N<sub>4</sub>O<sub>2</sub>  
**Molecular Weight** : 469.79  
**Target** : ERK  
**Solubility** : 10 mM in DMSO



## Biological Activity

Ulixertinib hydrochloride (BVD-523) is a potent, selective, reversible, ATP-competitive **ERK1/2** inhibitor with K<sub>i</sub> of 0.3/0.04 nM, respectively.

BVD-523 demonstrated excellent ERK1/2 kinase selectivity based on biochemical counter-screens against 75 kinases.

BVD-523 inhibits cellular proliferation and enhances caspase-3/7 activity in vitro while demonstrating substrate inhibition despite increased ERK1/2 phosphorylation.

BVD-523 (25-100 mg/kg, PO, BID) demonstrates in vivo antitumor activity in BRAFV600E-mutant cancer cell line (A375 cell line) xenograft models, and dose-dependent antitumor activity in KRASG12C-mutant pancreatic cell line xenograft model, MIAPaCa2.

BVD-523 yielded synergistic antiproliferative effects in a BRAFV600E-mutant melanoma cell line xenograft model when used in combination with BRAF inhibition.

## References

Germann UA, et al. *Mol Cancer Ther.* 2017 Nov;16(11):2351-2363.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com